Germline mutations in predisposition genes in pediatric cancer

New England Journal of Medicine

Volumn 373, Issue 24, 2015, Pages 2336-2346

  Zhang, Jinghui ^a   Walsh, Michael F ^a   Wu, Gang ^a   Edmonson, Michael N ^a   Gruber, Tanja A ^a   Easton, John ^a   Hedges, Dale ^a   Ma, Xiaotu ^a   Zhou, Xin ^a   Yergeau, Donald A ^a   Wilkinson, Mark R ^a   Vadodaria, Bhavin ^a   Chen, Xiang ^a   McGee, Rose B ^a   Dowell, Stacy Hines ^a   Nuccio, Regina ^a   Quinn, Emily ^a   Shurtleff, Sheila A ^a   Rusch, Michael ^a   Patel, Aman ^a   Becksfort, Jared B ^a   Wang, Shuoguo ^a   Weaver, Meaghann S ^a   Ding, Li ^b   Mardis, Elaine R ^b   Wilson, Richard K ^b   Gajjar, Amar ^a   Ellison, David W ^a   Pappo, Alberto S ^a   Pui, Ching Hon ^a   Nichols, Kim E ^a   Downing, James R ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BRCA2 PROTEIN; MISMATCH REPAIR PROTEIN PMS2; NEUROFIBROMIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ADOLESCENT; ADRENAL CORTEX TUMOR; ADULT; APC GENE; ARTICLE; AUTISM; BRCA2 GENE; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; DNA SEQUENCE; EWING SARCOMA; EXOME; FAMILY HISTORY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SELECTION; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NF1 GENE; OSTEOSARCOMA; PMS2 GENE; PREDICTION; PRIORITY JOURNAL; RB1 GENE; RETINOBLASTOMA; RHABDOMYOSARCOMA; RUNX1 GENE; TUMOR SUPPRESSOR GENE; CANCER REGISTRY; DOMINANT GENE; FEMALE; GENETICS; HUMAN GENOME; MALE; NEOPLASM; PROCEDURES; TUMOR GENE; YOUNG ADULT;

ADOLESCENT; AUTISTIC DISORDER; CHILD; FEMALE; GENES, DOMINANT; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GERM-LINE MUTATION; HUMANS; MALE; NEOPLASMS; SEER PROGRAM; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84949449519     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1508054     Document Type: Article

References (39)

1. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-83.
2. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008; (38): 1-93.
3. Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology. 6th ed. Philadelphia: Wolters Kluwer-Lippincott Williams & Wilkins Health, 2011.
4. Pui C-H. Childhood leukemias. 3rd ed. Cambridge, United Kingdom: Cambridge University Press, 2012.
5. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15: 565-74.
6. Bombard Y, Offit K, Robson ME. Risks to relatives in genomic research: a duty to warn? Am J Bioeth 2012; 12: 12-4.
7. Offit K, Groeger E, Turner S, Wadsworth EA, Weiser MA. The "duty to warn" a patient's family members about hereditary disease risks. JAMA 2004; 292: 1469-73.
8. Storm C, Agarwal R, Offit K. Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks? J Oncol Pract 2008; 4: 229-30.
9. Zhao M, Sun J, Zhao Z. TSGene: a Web resource for tumor suppressor genes. Nucleic Acids Res 2013; 41: D970-D976.
10. Edmonson MN, Zhang JH, Yan CH, Finney RP, Meerzaman DM, Buetow KH. Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format. Bioinformatics 2011; 27: 865-6.
11. Chen X, Gupta P, Wang J, et al. CONSERTING: integrating copy-number analysis with structural-variation detection. Nat Methods 2015; 12: 527-30.
12. Wang J, Mullighan CG, Easton J, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods 2011; 8: 652-4.
13. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-24.
14. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242-52.
15. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014; 46: 444-50.
16. Alter BP, Kupfer G. Fanconi anemia. Seattle: University of Washington, 2002.
17. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-9.
18. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39: 162-4.
19. Sawyer SL, Tian L, Kahkonen M, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov 2015; 5: 135-42.
20. Bougeard G, Sesboüé R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45: 535-8.
21. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011; 32: 177-95.
22. Cope JU, Tsokos M, Miller RW. Ewing sarcoma and sinonasal neuroectodermal tumors as second malignant tumors after retinoblastoma and other neoplasms. Med Pediatr Oncol 2001; 36: 290-4.
23. Mittal R, Al Awadi S, Sahar O, Behbehani AM. Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report. Med Princ Pract 2008; 17: 84-5.
24. Spunt SL, Rodriguez-Galindo C, Fuller CE, et al. Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer 2006; 107: 201-6.
25. Tahasildar N, Goni V, Bhagwat K, Tripathy SK, Panda BB. Ewing's sarcoma as second malignancy following a short latency in unilateral retinoblastoma. J Orthop Traumatol 2011; 12: 167-71.
26. Randall RL, Lessnick SL, Jones KB, et al. Is there a predisposition gene for Ewing's sarcoma? J Oncol 2010; 2010: 397632. 10.1155/2010/397632
27. Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer 2008; 7: 331-7.
28. Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM. Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. Cancer Biol Ther 2006; 5: 1098-102.
29. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
30. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
31. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of earlyonset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999; 59: 2011-7.
32. Cavalli LR, Singh B, Isaacs C, Dickson RB, Haddad BR. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. Cancer Genet Cytogenet 2004; 149: 38-43.
33. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE. Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer 2009; 8: 339-46.
34. Johnston JJ, Rubinstein WS, Facio FM, et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 2012; 91: 97-108.
35. Lucas AL, Shakya R, Lipsyc MD, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 2013; 19: 3396-403.
36. Osorio A, de la Hoya M, Rodriguez-Lopez R, et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002; 99: 305-9.
37. Staff S, Isola JJ, Johannsson O, Borg A, Tanner MM. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa. Br J Cancer 2001; 85: 1201-5.
38. Willems AJ, Dawson SJ, Samaratunga H, et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 2008; 14: 2953-61.
39. Knapke S, Nagarajan R, Correll J, Kent D, Burns K. Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr Blood Cancer 2012; 58: 85-9.